سه شنبه 8 مهر 1404
دوره 10، شماره 4 - ( 7-1403 )
جلد 10 شماره 4 صفحات 353-347 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rimaz S, Emir Alavi C, Soltanipour S, Sedighinejad A, Einollahzadeh R, Haghighi M, et al . Efficacy and Safety of Cisatracurium in Electroconvulsive Therapy: A Randomized, Single-blind, Clinical Trial. Caspian J Neurol Sci 2024; 10 (4) :347-353
URL: http://cjns.gums.ac.ir/article-1-730-fa.html
URL: http://cjns.gums.ac.ir/article-1-730-fa.html
Efficacy and Safety of Cisatracurium in Electroconvulsive Therapy: A Randomized, Single-blind, Clinical Trial. مجله علوم اعصاب کاسپین. 1403; 10 (4) :347-353
چکیده: (562 مشاهده)
Background: Electroconvulsive therapy (ECT) is widely accepted as a safe and effective treatment in psychiatric patients. Although succinylcholine is the choice of muscle relaxant in this process, its adverse effects and contraindications must be considered.
Objectives: This study investigated the efficacy of cisatracurium as an alternative in ECT patients.
Materials & Methods: This single-blind clinical trial was performed in an academic hospital in Northern Iran from July 2023 to March 2024. A total of 62 eligible ECT patients were enrolled in the survey and randomly divided into succinylcholine (0.5 mg/kg) and cisatracurium (0.1 mg/kg) groups. Seizure duration, mean arterial pressure, heart rate, the time to return to spontaneous breathing, and recovery time were recorded and compared between the two groups.
Results: No significant difference was observed between the two groups regarding seizure duration and hemodynamic parameters (P>0.05). However, the time to return to spontaneous breathing (P=0.0001) and recovery time (P=0.0001) were significantly longer in the cisatracurium group. None of the patients was affected by serious adverse effects.
Conclusion: Cisatracurium is a safe alternative to succinylcholine and can be administrated during ECT.
Objectives: This study investigated the efficacy of cisatracurium as an alternative in ECT patients.
Materials & Methods: This single-blind clinical trial was performed in an academic hospital in Northern Iran from July 2023 to March 2024. A total of 62 eligible ECT patients were enrolled in the survey and randomly divided into succinylcholine (0.5 mg/kg) and cisatracurium (0.1 mg/kg) groups. Seizure duration, mean arterial pressure, heart rate, the time to return to spontaneous breathing, and recovery time were recorded and compared between the two groups.
Results: No significant difference was observed between the two groups regarding seizure duration and hemodynamic parameters (P>0.05). However, the time to return to spontaneous breathing (P=0.0001) and recovery time (P=0.0001) were significantly longer in the cisatracurium group. None of the patients was affected by serious adverse effects.
Conclusion: Cisatracurium is a safe alternative to succinylcholine and can be administrated during ECT.
| بازنشر اطلاعات | |
 | این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
